Peripheral biomarkers in animal models for major depressive disorder

Disease Markers

Volumn 35, Issue 1, 2013, Pages 33-41

  Carboni, Lucia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; MESSENGER RNA; STRESS HORMONE; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID METABOLISM; ANHEDONIA; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BEHAVIOR CHANGE; BLOOD VESSEL REACTIVITY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; ENDOPHENOTYPE; EXERCISE; GENETIC SELECTION; HUMAN; HYPERTENSION; IMMOBILIZATION STRESS; IMMUNE DYSREGULATION; INSULIN RESISTANCE; MAJOR DEPRESSION; MATERNAL DEPRIVATION; MENTAL STRESS; MOOD CHANGE; NEUROBIOLOGY; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PHYSIOTHERAPY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REVIEW; SLEEP DEPRIVATION; SLEEP DISORDER; SOCIAL STRESS; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

ANIMALIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 84883067609     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/284543     Document Type: Review

References (88)

1. R. C. Kessler, P. Berglund, O. Demler et al., "The epidemiology for major depressive disorder: results from the national comorbidity survey replication (NCS-R)," The Journal for the American Medical Association, vol. 289, no. 23, pp. 3095-3105, 2003.
2. H. U. Wittchen, F. Jacobi, J. Rehm et al., "The size and burden for mental disorders and other disorders for the brain in Europe 2010," European Neuropsychopharmacology, vol. 21, no. 9, pp. 655-679, 2011.
3. A. Halaris, "Comorbidity between depression and cardiovascular disease," International Angiology, vol. 28, no. 2, pp. 92-99, 2009.
4. B. N. Renn, L. Feliciano, and D. L. Segal, "The bidirectional relationship for depression and diabetes: a systematic review," Clinical Psychology Review, vol. 31, no. 8, pp. 1239-1246, 2011.
5. American Psychiatric Association, Diagnostic and Statistical Manual for Mental Disorders, Text Revision, American Psychiatric Association, Washington DC, USA, 4th edition, 2000.
6. A. Baudry, S. Mouillet-Richard, J. Launay, and O. Kellermann, "New views on antidepressant action," Current Opinion in Neurobiology, vol. 21, no. 6, pp. 858-865, 2011.
7. R. S. Duman and B. Voleti, "Signaling pathways underlying the pathophysiology and treatment for depression: novel mechanisms for rapid-acting agents," Trends in Neurosciences, vol. 35, no. 1, pp. 47-56, 2012.
8. A. T. Beck and D. J. A. Dozois, "Cognitive therapy: current status and future directions," Annual Review for Medicine, vol. 62, pp. 397-409, 2011.
9. M. F. de Mello, J. de Jesus Mari, J. Bacaltchuk, H. Verdeli, and R. Neugebauer, "A systematic review for research findings on the efficacy for interpersonal therapy for depressive disorders," European Archives for Psychiatry and Clinical Neuroscience, vol. 255, no. 2, pp. 75-82, 2005.
10. The UK ECT Review Group, "Efficacy and safety for electrocon-vulsive therapy in depressive disorders: a systematic review and meta-analysis," The Lancet, vol. 361, no. 9360, pp. 799-808, 2003.
11. F. Padberg and M. S. George, "Repetitive transcranial magnetic stimulation for the prefrontal cortex in depression," Experimental Neurology, vol. 219, no. 1, pp. 2-13, 2009.
12. G. E. Mead, W. Morley, P. Campbell, C. A. Greig, M. McMurdo, and D. A. Lawlor, "Exercise for depression," Cochrane Database for Systematic Reviews, no. 4, Article ID CD004366, 2008.
13. H. Giedke and F. Schwäzler, "Therapeutic use for sleep deprivation in depression," Sleep Medicine Reviews, vol. 6, no. 5, pp. 361-377, 2002.
14. J. C. Fournier, R. J. DeRubeis, S. D. Hollon et al., "Antidepressant drug effects and depression severity: a patient-level meta-analysis," The Journal for the American Medical Association, vol. 303, no. 1, pp. 47-53, 2010.
15. A. Fekadu, S. C. Wooderson, K. Markopoulo, C. Donaldson, A. Papadopoulos, and A. J. Cleare, "What happens to patients with treatment-resistant depression? A systematic review for medium to long term outcome studies," Journal for Affective Disorders, vol. 116, no. 1-2, pp. 4-11, 2009.
16. M. L. Wong and J. Licinio, "From monoamines to genomic targets: a paradigm shift for drug discovery in depression," Nature Reviews Drug Discovery, vol. 3, no. 2, pp. 136-151, 2004.
17. G. Griebel and F. Holsboer, "Neuropeptide receptor ligands as drugs for psychiatric diseases: the end for the beginning?" Nature Reviews Drug Discovery, vol. 11, no. 6, pp. 462-478, 2012.
18. R. H. Belmaker and G. Agam, "Major depressive disorder," The New England Journal for Medicine, vol. 358, no. 1, pp. 55-68, 2008.
19. H. K. Manji, W. C. Drevets, and D. S. Charney, "The cellular neurobiology for depression," Nature Medicine, vol. 7, no. 5, pp. 541-547, 2001.
20. V. Krishnan and E. J. Nestler, "The molecular neurobiology for depression," Nature, vol. 455, no. 7215, pp. 894-902, 2008.
21. G. Hasler, W. C. Drevets, H. K. Manji, and D. S. Charney, "Discovering endophenotypes for major depression," Neuropsychopharmacology, vol. 29, no. 10, pp. 1765-1781, 2004.
22. E. Palazidou, "The neurobiology for depression," The British Medical Bulletin, vol. 101, no. 1, pp. 127-145, 2012.
23. E. Castrén, V. Võikar, and T. Rantamäki, "Role for neurotrophic factors in depression," Current Opinion in Pharmacology, vol. 7, no. 1, pp. 18-21, 2007.
24. M. Maes, R. Yirmyia, J. Noraberg et al., "The inflammatory & neurodegenerative (I&ND) hypothesis for depression: leads for future research and new drug developments in depression," Metabolic Brain Disease, vol. 24, no. 1, pp. 27-53, 2009.
25. N. Kronfeld-Schor and H. Einat, "Circadian rhythms and depression: human psychopathology and animal models," Neuropharmacology, vol. 62, no. 1, pp. 101-114, 2012.
26. L. Capuron and R. Dantzer, "Cytokines and depression: the need for a new paradigm," Brain, Behavior, and Immunity, vol. 17, supplement 1, pp. S119-S124, 2003.
27. R. Yirmiya and I. Goshen, "Immune modulation for learning, memory, neural plasticity and neurogenesis," Brain, Behavior, and Immunity, vol. 25, no. 2, pp. 181-213, 2011.
28. C. Song and H. Wang, "Cytokines mediated inflammation and decreased neurogenesis in animal models for depression," Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 3, pp. 760-768, 2011.
29. H. Anisman and Z. Merali, "Cytokines, stress and depressive illness: brain-immune interactions," Annals for Medicine, vol. 35, no. 1, pp. 2-11, 2003.
30. A. H. Miller, V. Maletic, and C. L. Raison, "Inflammation and its discontents: the role for cytokines in the pathophysiology for major depression," Biological Psychiatry, vol. 65, no. 9, pp. 732-741, 2009.
31. H. D. Schmidt, R. C. Shelton, and R. S. Duman, "Functional biomarkers for depression: diagnosis, treatment, and pathophysiology," Neuropsychopharmacology, vol. 36, no. 12, pp. 2375-2394, 2011.
32. A. F. Leuchter, I. A. Cook, S. P. Hamilton et al., "Biomarkers to predict antidepressant response," Current Psychiatry Reports, vol. 12, no. 6, pp. 553-562, 2010.
33. *D) trial," Molecular Diagnosis and Therapy, vol. 12, no. 5, pp. 321-330, 2008.
34. M. J. Taylor, N. Freemantle, J. R. Geddes, and Z. Bhagwagar, "Early onset for selective serotonin reuptake inhibitor antide-pressant action: systematic review and meta-analysis," Archives for General Psychiatry, vol. 63, no. 11, pp. 1217-1223, 2006.
35. G. I. Papakostas, R. H. Perlis, M. J. Scalia, T. J. Petersen, and M. Fava, "A meta-analysis for early sustained response rates between antidepressants and placebo for the treatment for major depressive disorder," Journal for Clinical Psychopharmacology, vol. 26, no. 1, pp. 56-60, 2006.
36. A. Steiger and M. Kimura, "Wake and sleep EEG provide biomarkers in depression," Journal for Psychiatric Research, vol. 44, no. 4, pp. 242-252, 2010.
37. M. P. Quinones and R. Kaddurah-Daouk, "Metabolomics tools for identifying biomarkers for neuropsychiatric diseases," Neurobiology for Disease, vol. 35, no. 2, pp. 165-176, 2009.
38. O. Berton, C. G. Hahn, and M. E. Thase, "Are we getting closer to valid translational models for major depression?" Science, vol. 338, no. 6103, pp. 75-79, 2012.
39. B. A. Samuels, E. D. Leonardo, R. Gadient et al., "Modeling treatment-resistant depression," Neuropharmacology, vol. 61, no. 3, pp. 408-413, 2011.
40. J. F. Cryan and D. A. Slattery, "Animal models for mood disorders: recent developments," Current Opinion in Psychiatry, vol. 20, no. 1, pp. 1-7, 2007.
41. E. J. Nestler and S. E. Hyman, "Animal models for neuropsychiatric disorders," Nature Neuroscience, vol. 13, no. 10, pp. 1161-1169, 2010.
42. M. F. O'Neil and N. A. Moore, "Animal models for depression: are there any?" Human Psychopharmacology, vol. 18, no. 4, pp. 239-254, 2003.
43. C. R. Pryce and E. Seifritz, "A translational research framework for enhanced validity for mouse models for psychopathological states in depression," Psychoneuroendocrinology, vol. 36, no. 3, pp. 308-329, 2011.
44. M. V. Schmidt, X. Wang, and O. C. Meijer, "Early life stress paradigms in rodents: potential animal models for depression?" Psychopharmacology, vol. 214, no. 1, pp. 131-140, 2011.
45. C. Song and B.E. Leonard, "The olfactory bulbectomised ratasa model for depression," Neuroscience and Biobehavioral Reviews, vol. 29, no. 4-5, pp. 627-647, 2005.
46. D. H. Overstreet, E. Friedman, A. A. Mathé, and G. Yadid, "The flinders sensitive line rat: a selectively bred putative animal model for depression," Neuroscience and Biobehavioral Reviews, vol. 29, no. 4-5, pp. 739-759, 2005.
47. F. A. Henn and B. Vollmayr, "Stress models for depression: forming genetically vulnerable strains," Neuroscience and Biobehavioral Reviews, vol. 29, no. 4-5, pp. 799-804, 2005.
48. R. Dantzer, J. C. O'Connor, M. A. Lawson, and K. W. Kelley, "Inflammation-associated depression: from serotonin to kynurenine," Psychoneuroendocrinology, vol. 36, no. 3, pp. 426-436, 2011.
49. M. Maes, M. Berk, L. Goehler et al., "Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways," BMC Medicine, vol. 10, article 66, 2012.
50. H. Abe, N. Hidaka, C. Kawagoe et al., "Prenatal psychological stress causes higher emotionality, depression-like behavior, and elevated activity in the hypothalamo-pituitary-adrenal axis," Neuroscience Research, vol. 59, no. 2, pp. 145-151, 2007.
51. M. Razzoli, E. Roncari, A. Guidi et al., "Conditioning properties for social subordination in rats: behavioral and biochemical correlates for anxiety," Hormones and Behavior, vol. 50, no. 2, pp. 245-251, 2006.
52. M. Razzoli, L. Carboni, A. Guidi, P. Gerrard, and R. Arban, "Social defeat-induced contextual conditioning differentially imprints behavioral and adrenal reactivity: a time-course study in the rat," Physiology and Behavior, vol. 92, no. 4, pp. 734-740, 2007.
53. M. Razzoli, L. Carboni, and R. Arban, "Alterations for behavioral and endocrinological reactivity induced by 3 brief social defeats in rats: relevance to human psychopathology," Psychoneuroendocrinology, vol. 34, no. 9, pp. 1405-1416, 2009.
54. M. Razzoli, L. Carboni, M. Andreoli, A. Ballottari, and R. Arban, "Different susceptibility to social defeat stress for BalbC and C57BL6/J mice," Behavioural Brain Research, vol. 216, no. 1, pp. 100-108, 2011.
55. M. Razzoli, E. Domenici, L. Carboni et al., "A role for BDNF/TrkB signaling in behavioral and physiological consequences for social defeat stress," Genes, Brain and Behavior, vol. 10, no. 4, pp. 424-433, 2011.
56. N. Bowens, W. Heydendael, S. Bhatnagar, and L. Jacobson, "Lack for elevations in glucocorticoids correlates with dysphoria-like behavior after repeated social defeat," Physiology and Behavior, vol. 105, no. 4, pp. 958-965, 2012.
57. C. Touma, T. Fenzl, J. Ruschel et al., "Rhythmicity in mice selected for extremes in stress reactivity: behavioural, endocrine and sleep changes resembling endophenotypes for major depression," PLoS ONE, vol. 4, no. 1, Article ID e4325, 2009.
58. A. Blugeot, C. Rivat, E. Bouvier et al., "Vulnerability to depression: from brain neuroplasticity to identification for biomarkers," Journal for Neuroscience, vol. 31, no. 36, pp. 12889-12899, 2011.
59. X. Y. Lu, C. S. Kim, A. Frazer, and W. Zhang, "Leptin: a potential novel antidepressant," Proceedings for the National Academy for Sciences for the United States for America, vol. 103, no. 5, pp. 1593-1598, 2006.
60. J. C. Chuang, V. Krishnan, H. G. Yu et al., "A β3- adrenergicleptin-melanocortin circuit regulates behavioral and metabolic changes induced by chronic stress," Biological Psychiatry, vol. 67, no. 11, pp. 1075-1082, 2010.
61. A. C. D'Audiffret, S. J. Frisbee, P. A. Stapleton, A. G. Goodwill, E. Isingrini, and J. C. Frisbee, "Depressive behavior and vascular dysfunction: a link between clinical depression and vascular disease?" Journal for Applied Physiology, vol. 108, no. 5, pp. 1041-1051, 2010.
62. J. C. O'Connor, M. A. Lawson, C. André et al., "Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice," Molecular Psychiatry, vol. 14, no. 5, pp. 511-522, 2009.
63. J. C. O'Connor, C. André, Y. Wang et al., "Interferon-γ and tumor necrosis factor-α mediate the upregulation for indoleamine 2,3-dioxygenase and the induction for depressive-like behavior in mice in response to bacillus calmette-guérin," Journal for Neuroscience, vol. 29, no. 13, pp. 4200-4209, 2009.
64. G. Naert, G. Ixart, T. Maurice, L. Tapia-Arancibia, and L. Givalois, "Brain-derived neurotrophic factor and hypothalamic-pituitary-adrenal axis adaptation processes in a depressive-like state induced by chronic restraint stress," Molecular and Cellular Neuroscience, vol. 46, no. 1, pp. 55-66, 2011.
65. F. Cirulli, N. Francia, I. Branchi et al., "Changes in plasma levels for BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques," Psychoneuroendocrinology, vol. 34, no. 2, pp. 172-180, 2009.
66. A. Moranis, J. Delpech, V. de Smedt-Peyrusse et al., "Long term adequate n-3 polyunsaturated fatty acid diet protects from depressive-like behavior but not from working memory disruption and brain cytokine expression in aged mice," Brain, Behavior, and Immunity, vol. 26, no. 5, pp. 721-731, 2012.
67. L. Capuron, S. Schroecksnadel, C. Féart et al., "Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms," Biological Psychiatry, vol. 70, no. 2, pp. 175-182, 2011.
68. K. Malki, R. Uher, J. Paya-Cano et al., "Convergent animal and human evidence suggests a role for PPM1A gene in response to antidepressants," Biological Psychiatry, vol. 69, no. 4, pp. 360-365, 2011.
69. B. M. Andrus, K. Blizinsky, P. T. Vedell et al., "Gene expression patterns in the hippocampus and amygdala for endogenous depression and chronic stress models," Molecular Psychiatry, vol. 17, no. 1, pp. 49-61, 2012.
70. K. Pajer, B. M. Andrus, W. Gardner et al., "Discovery for blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression," Translational Psychiatry, vol. 2, article e101, 2012.
71. J. P. R. Jacobsen, W. B. Siesser, B. D. Sachs et al., "Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice," Molecular Psychiatry, vol. 17, no. 7, pp. 694-704, 2012.
72. Z. Sarnyai, M. Alsaif, S. Bahn et al., "Behavioral and molecular biomarkers in translational animal models for neuropsychiatric disorders," International Review for Neurobiology, vol. 101, pp. 203-238, 2011.
73. L. Carboni, S. Becchi, C. Piubelli et al., "Early-life stress and antidepressants modulate peripheral biomarkers in a geneenvironment rat model for depression," Progress in NeuroPsychopharmacology and Biological Psychiatry, vol. 34, no. 6, pp. 1037-1048, 2010.
74. S. Zheng, M. Yu, X. Lu et al., "Urinary metabonomic study on biochemical changes in chronic unpredictable mild stress model for depression," Clinica Chimica Acta, vol. 411, no. 3-4, pp. 204-209, 2010.
75. B. Elfving, P. H. Plougmann, H. K. Müller, A. A. Mathé, R. Rosenberg, and G. Wegener, "Inverse correlation for brain and blood BDNF levels in a genetic rat model for depression," International Journal for Neuropsychopharmacology, vol. 13, no. 5, pp. 563-572, 2010.
76. A. Sartorius, R. Hellweg, J. Litzke et al., "Correlations and discrepancies between serum and brain tissue levels for neurotrophins after electroconvulsive treatment in rats," Pharmacopsychiatry, vol. 42, no. 6, pp. 270-276, 2009.
77. K. R. Luo, C. J. Hong, Y. J. Liou, S. J. Hou, Y. H. Huang, and S. J. Tsai, "Differential regulation for neurotrophin S100B and BDNF in two rat models for depression," Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 8, pp. 1433-1439, 2010.
78. C. M. Pariante and S. L. Lightman, "The HPA axis in major depression: classical theories and new developments," Trends in Neurosciences, vol. 31, no. 9, pp. 464-468, 2008.
79. C. F. Gillespie and C. B. Nemeroff, "Hypercortisolemia and depression," Psychosomatic Medicine, vol. 67, supplement 1, pp. S26-S28, 2005.
80. B. C. Detanico, A. L. Piato, J. J. Freitas et al., "Antidepressant- like effects for melatonin in the mouse chronic mild stress model," European Journal for Pharmacology, vol. 607, no. 1-3, pp. 121-125, 2009.
81. J. Maniam and M. J. Morris, "Voluntary exercise and palatable high-fat diet both improve behavioural profile and stress responses in male rats exposed to early life stress: role for hippocampus," Psychoneuroendocrinology, vol. 35, no. 10, pp. 1553-1564, 2010.
82. E. C. Borsonelo, D. Suchecki, and J. C. F. Galduróz, "Effect for fish oil and coconut fat supplementation on depressive-type behavior and corticosterone levels for prenatally stressed male rats," Brain Research, vol. 1385, pp. 144-150, 2011.
83. C. Song, Y. Z. Xiang, and M. Manku, "Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model for depression: effects for chronic ethyl-eicosapentaenoate treatment," Journal for Neuroscience, vol. 29, no. 1, pp. 14-22, 2009.
84. S. Bison, M. Razzoli, R. Arban, F. Michielin, S. Bertani, and L. Carboni, "Effect for the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats," European Journal for Pharmacology, vol. 661, no. 1-3, pp. 49-56, 2011.
85. H. Eyre and B. T. Baune, "Neuroimmunological effects for physical exercise in depression," Brain, Behavior, and Immunity, vol. 26, no. 2, pp. 251-266, 2012.
86. G. A. Behr, J. C. Moreira, and B. N. Frey, "Preclinical and clinical evidence for antioxidant effects for antidepressant agents: implications for the pathophysiology for major depressive disorder," Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 609421, 13 pages, 2012.
87. K. Watanabe, E. Hashimoto, W. Ukai et al., "Effect for antidepressants on brain-derived neurotrophic factor (BDNF) release from platelets in the rats," Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 8, pp. 1450-1454, 2010.
88. R. S. Duman and L. M. Monteggia, "A neurotrophic model for stress-related mood disorders," Biological Psychiatry, vol. 59, no. 12, pp. 1116-1127, 2006.